Anti-Human CD40/TNFRSF5 Reference Antibody (Cifurtilimab, RUO)

Description: Cifurtilimab (BS10812) is a research-grade recombinant antibody targeting CD40. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Tumornecrosisfactorreceptorsuperfamilymember5,B-cellsurfaceantigenCD40,Bp50,CD40Lreceptor,TNFRSF5,CDw40,CD40
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: SEA-CD40,hS2C6nf,SEACD40,SEACD40
Background: Tumor necrosis factor receptor superfamily member 5 (CD40/TNFRSF5) is a ~30 kDa protein. Receptor for TNFSF5/CD40LG. Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion.
References:
1. Takada, YK. et al. (2019) Journal of immunology (Baltimore, Md. : 1950) 203, 1383-1391. PMID: 31331973
Note: For research use only. Not suitable for clinical or therapeutic use.